GENERAL25 Sept 2026
AI-led drug discovery to create decade-long CDMO tailwind: Harini Dedhia
AI is now a basic tool for pharma companies, says fund manager Harini Dedhia of Tamohara Investment Managers. It helps them find new drugs faster and with far better odds of success. She expects this to give CDMO (contract development and manufacturing organisation) businesses a strong run of work lasting about a decade. If you hold pharma or CDMO shares, review them calmly.
Key Statutory Highlights
- Harini Dedhia is a fund manager at Tamohara Investment Managers.
- She says AI works as a utility for pharma companies, delivering drug discovery in a shorter time frame.
- AI-led drug discovery is expected to create a decade-long tailwind for CDMO businesses.
Actionable Advice for Taxpayers / Founders:If you invest in pharma or drug manufacturing shares, treat this as one expert view and not a sure outcome. Speak to your advisor before making any portfolio change.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: